SESSION TITLE: Lung Cancer Screening in the Real World
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Sunday, October 23, 2016 at 04:30 PM - 05:30 PM
PURPOSE: Bronchoscopy is frequently used for the evaluation of suspicious pulmonary lesions, but its sensitivity for detecting lung cancer is limited. Recently, a bronchial genomic classifier (Percepta®) was validated to improve the sensitivity of bronchoscopy for lung cancer detection, demonstrating a high sensitivity and negative predictive value among patients at low to intermediate risk for lung cancer with an inconclusive bronchoscopy. Such a classifier may reduce the rate that physicians recommend more invasive testing among patients with an inconclusive bronchoscopy. The objective for this study was to determine if variations in physician practice patterns influence the impact of a genomic classifier result that down-classifies a patient from intermediate risk to low risk (<10%) for lung cancer.